ArticleBreast cancer (Tokyo, Japan)2025
A nomogram to predict the benefit of postmastectomy radiotherapy in breast cancer with nodal micrometastases.
Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe role of postmastectomy radiotherapy (PMRT) in breast cancer (BC) with nodal micrometastases (N1mic) remains unclear. This study aimed to evaluate the efficacy of PMRT in T1-2N1mic BC patients who have undergone mastectomy.
methodsFemale patients with T1-2N1mic BC who underwent mastectomy and were registered in the Surveillance, Epidemiology, and End Results database between 2010 and 2017. The chi-square test, logistic regression analysis, Kaplan-Meier methods, and multivariate Cox proportional hazards analysis were used for statistical analyses. Nomograms for predicting breast cancer-specific survival (BCSS) and overall survival (OS) were created by integrating the independent prognostic factors.
resultsA total of 5948 eligible patients were included in this study. A total of 1207 patients (20.3%) received PMRT, while 4741 patients (79.7%) did not. The use of PMRT increased over the study period, from 15.7% in 2010 to 23.8% in 2017 (P < 0.001). The multivariate Cox proportional hazards analysis showed that PMRT did not improve BCSS and OS. Nomograms were established based on the independent prognostic factors to predict the BCSS and CSS of patients. Regarding BCSS, there were 3627 patients (61.0%) classified as low-risk and 2321 patients (39.0%) classified as high-risk using a cutoff point of 125, PMRT did not improve BCSS in patients with low-risk (P = 0.697) and high-risk (P = 0.149) groups. Regarding OS, there were 4791 patients (80.5%) classified as low-risk and 1157 patients (19.5%) classified as high-risk using a cutoff point of 130, patients who received PMRT had significantly better 5-year OS than those who did not receive PMRT (P = 0.047), while similar outcomes were found between the treatment arms in the low-risk group (P = 0.575).
conclusionsWhile our findings suggest that PMRT does not enhance survival outcomes in T1-T2N1mic BC patients, it may offer a survival advantage in high-risk subgroups.
Indexed as
Identifiers
40335870What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.